创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology PDC High-Throughput In Vitro Drug Efficacy Platform: Introduction of Technical Advantages

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-07-10 16:19
  • Views:

(Summary description)In the field of drug discovery and development, an efficient and accurate drug efficacy evaluation platform plays a crucial role in the successful development and clinical application of new drugs. With its unique technology and advantages, InnoModels' PDC high-throughput in vitro drug efficacy platform provides unprecedented accuracy and reliability for drug R&D and clinical treatment, and has become an important force leading the field of drug evaluation.

InnoModels Biotechnology PDC High-Throughput In Vitro Drug Efficacy Platform: Introduction of Technical Advantages

(Summary description)In the field of drug discovery and development, an efficient and accurate drug efficacy evaluation platform plays a crucial role in the successful development and clinical application of new drugs. With its unique technology and advantages, InnoModels' PDC high-throughput in vitro drug efficacy platform provides unprecedented accuracy and reliability for drug R&D and clinical treatment, and has become an important force leading the field of drug evaluation.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-07-10 16:19
  • Views:
Information

In the field of drug discovery and development, an efficient and accurate drug efficacy evaluation platform plays a crucial role in the successful development and clinical application of new drugs. With its unique technology and advantages, InnoModels' PDC high-throughput in vitro drug efficacy platform provides unprecedented accuracy and reliability for drug R&D and clinical treatment, and has become an important force leading the field of drug evaluation.
1、Highly consistent primary cells
The core of InnoModels' PDC high-throughput in vitro drug efficacy platform lies in its ability to utilize cutting-edge technology to obtain highly consistent primary cells with the patient from the digested products of the PDX (human-derived tumor xenograft) model. Such cells not only retain complex cell subpopulations and biological characteristics, but also more closely resemble the clinical situation, allowing for more realistic and reliable drug action and response. Through this platform, researchers can simulate the clinical environment in vitro for drug screening and efficacy evaluation, providing powerful technical support for new drug development.
2. Pharmacodynamic response and clinical relevance
The PDC high-throughput in vitro drug efficacy platform is not only applicable to the screening of test drugs and models, but also capable of predicting the clinical efficacy of drugs. By comparing the subject drug with counterpart drugs (e.g., drugs with similar mechanism of action or standardized therapeutic drugs), researchers can predict the clinical value of the drug and provide a scientific basis for further development and application of the drug. This highly clinically relevant drug efficacy evaluation helps to reduce the risk and cost of new drug development and improve the success rate of R&D.

 


3、Multi-dimensional application
The PDC high-throughput in vitro drug efficacy platform of InnoModels Biotechnology has a wide range of applications, not only for drug screening, but also in multiple dimensions. For example, by comparing the efficacy rates of different cancer models, the indications of drugs can be determined; by comparing the differences in genetic characteristics between sensitive and resistant models, biomarkers that can predict drug efficacy can be searched. In addition, the platform can be used in the field of personalized medicine to provide patients with more precise treatment plans.
4、Efficient Data Processing Capability
Equipped with an advanced data analysis system, the InnoModels Biotechnology PDC high-throughput in vitro drug efficacy platform is capable of automated processing and analysis of experimental data, greatly improving the efficiency and accuracy of data processing. Researchers can intuitively understand the experimental results through the visualization reports provided by the platform, thus better guiding the subsequent research work. This efficient data processing capability makes the drug development process more efficient and convenient.
5、Lead the innovation in the field of drug evaluation
The emergence of the InnoModels Biotechnology PDC high-throughput in vitro drug efficacy platform has brought unprecedented precision and reliability to drug development and clinical treatment. The platform not only focuses on drug screening, but also pays more attention to the prospect of drug clinical application. Through continuous technological innovation and optimization, the platform will inject more innovation and progress into the field of drug evaluation and promote the continuous development of the drug R&D field.
In conclusion, with its unique technology and advantages, InnoModels Biotechnology PDC high-throughput in vitro drug efficacy platform provides powerful technical support for drug development and clinical treatment. With the continuous development of the biopharmaceutical field, the platform will play a greater role in the future, injecting more confidence and momentum for the success of new drug development and clinical application.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司